Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GALK1 | P51570 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.56 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001318 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL8838912 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL18718056 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL9155988 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL20056672 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL15504372 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5026360 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL9849387 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5026366 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL18733414 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108794547-A | A kind of preparation method of 3-O- carbamyls sweet dew saccharide donor derivative, bleomycin disaccharides and its precursor | 广州中医药大学(广州中医药研究院) | 2018-11-13 | — | — | CN | claimed |
| CN-108026340-A | Polyolefin compositions | SABIC环球技术有限责任公司 | 2018-05-11 | — | — | CN | claimed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11147219-B2 | Methods and systems for growing plants using silicate-based substrates, cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives, and formulations, process and systems for the same | INNOVATION HAMMER, LLC (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3808177-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2021-04-21 | — | — | EP | disclosed |
| EP-3783093-A2 | METHOD FOR GROWING PLANTS USING SILICATE MICROBEADS AND PHOTOSAFENING BY UTILIZATION OF EXOGENOUS GLYCOPYRANOSIDES | Innovation Hammer LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-17 | — | — | US | disclosed |
| EP-2782990-B1 | METHOD FOR GROWING PLANTS USING SILICATE MICROBEADS AND PHOTOSAFENING BY UTILIZATION OF EXOGENOUS GLYCOPYRANOSIDES | INNOVATION HAMMER LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3238738-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2020-09-23 | — | — | EP | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20200113143-A1 | Methods And Systems For Growing Plants Using Silicate-Based Substrates, Cultivation Of Enhanced Photosynthetic Productivity And Photosafening By Utilization Of Exogenous Glycopyranosides For Endogenous Glycopyranosyl-Protein Derivatives, And Formulations, Processes And Systems For The Same | INNOVATION HAMMER LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-6462193-B1 | ADDING 3-AZIDO-2-HYDROXYPROPANALDEHYDE WITH DIHYDROXYACETONE PHOSPHATE USING AN ALDOLASE, HYDROLYZING THE INTERMEDIATE WITH ACID PHOSPHATASE, ISOMERIZING USING AN ISOMERASE, CYCLIZING USING REDUCTIVE AMINATION TO PRODUCE TETRAHYDROXYAZEPINE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
| WO-1998037218-A1 | HYDROXYAZEPANES AS INHIBITORS OF GLYCOSIDASE AND HIV PROTEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-27 | — | — | WO | disclosed |
| US-5633261-A | ANTITUMOR AGENTS | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1997-05-27 | — | — | US | disclosed |
| US-5621106-A | REACTING WITH DIALKYLTIN OXIDE; ACYLATION; ALKYLATION | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1997-04-15 | — | — | US | disclosed |
| US-5466809-A | From aminomannose, antitumor agents, castanospermine | TORONTO RESEARCH CHEMICALS, INC. (CA) | 1995-11-14 | — | — | US | disclosed |
| EP-0424350-B1 | Derivatives of 1,4-dideoxy-1,4-imino-d-mannitol | MONSANTO CO (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5041555-A | Mannosidase inhibitors | MONSANTO COMPANY (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0424350-A1 | Derivatives of 1,4-dideoxy-1,4-imino-d-mannitol | MONSANTO COMPANY (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4996329-A | Enzyme inhibitors, viricides | MONSANTO COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | SLC6A2 3674/4885SYNJ2 3826/4885KDM4E 3210/4885 |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | CETP, LCAT, LIPA | SLC6A2 1701/4885SYNJ2 710/4885KDM4E 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.